已发表论文

环丙酚用于不同体重指数患者无痛结肠镜检查麻醉的有效性和安全性:一项前瞻性、单中心、观察性研究

 

Authors Li Y , Yuan M, Zhang P, Zhou T, Zhang M, Xu J

Received 18 September 2024

Accepted for publication 28 December 2024

Published 3 January 2025 Volume 2025:19 Pages 1—9

DOI https://doi.org/10.2147/DDDT.S496783

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Prof. Dr. Georgios Panos

Yaqi Li, Mailong Yuan, Ping Zhang, Tao Zhou, Mingsheng Zhang, Jinhui Xu

Department of Anesthesiology, Jiangxi Provincial People’s Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi, 330006, People’s Republic of China

Correspondence: Jinhui Xu, Department of Anesthesiology, Jiangxi Provincial People’s Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, 330006, People’s Republic of China, Email mzkxjh@163.com

Background: Ciprofol, a novel intravenous anesthetic derived from propofol, exhibits high lipophilicity. Its pharmacokinetics and pharmacodynamics may vary across different body mass indices (BMI) categories, but data on its optimal dosing as well as its safety and efficacy during colonoscopy anesthesia in varying BMI groups are lacking.
Objective: To evaluate the efficacy and safety of ciprofol during anesthesia for painless colonoscopy in patients with varying BMI, and to explore the correlation between BMI and induction dose.
Methods: The BMI classification standard used in this study followed the criteria used in China. This prospective, single-center, observational study enrolled two hundred patients and they were divided into three groups with BMI: Group A (18.5– 23.9 kg/m²), Group B (24– 27.9 kg/m²), and Group C (28– 39.9 kg/m²). Ciprofol was administered slowly (3 seconds per milliliter) until MOAA/S ≤ 1. Induction dose, additional ciprofol use, procedure duration, recovery time, vital signs, and adverse events were recorded.
Results: The total induction dose was higher in Groups B and C than in Group A, with Group C receiving the highest dose (P< 0.001). Dose per kilogram of TBW was lower in Groups B and C (P< 0.001), while corrected body weight (CBW)-based dosing showed no significant difference between groups (P=0.287). There were no significant differences in procedure duration, recovery time, or adverse events among groups.
Conclusion: Ciprofol is safe and effective for colonoscopy anesthesia across BMI groups, offering stable hemodynamics without prolonging recovery or increasing adverse events. CBW is a reliable dosing metric for overweight and obese patients.

Keywords: ciprofol, body mass index, colonoscopy, anesthesia